Edgar Filing: Li Xinzhou - Form 4

Li Xinzhou											
Form 4											
January 03, 2	013										
FORM	4	р статрс	SECUE	TTIES A		TTA NI	CE C	OMMISSION	OMB APPROVAL		
UNITED STATES SE					, D.C. 2054		GE U	UMMISSION	OMB Number:	3235-0287	
Check this if no long subject to Section 16 Form 4 or	F CHANGES IN BENEFICIAL OWN SECURITIES						Expires: January 3 200 Estimated average burden hours per response 0				
Form 5 obligation may conti <i>See</i> Instru 1(b).	nue. 20(h) of the Investment Company Act of 1955 of Section										
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> Li Xinzhou			2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer			
No [N				y Pharma	aceuticals,	Inc.		(Check all applicable)			
(M				Earliest Tr ay/Year) 012	ransaction			Director _X 10% Owner Officer (give title _X Other (specify below) Pres.Naqu Area Pioneer Pharma			
	(Street)	et) 4. If Amendment, Date Original Filed(Month/Day/Year)						 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
SHANGHAI CHINA 2012	·							Form filed by M Person	ore than One Re	porting	
(City)	(State)	(Zip)	Tabl	e I - Non-I	Derivative Se	curiti	es Acqu	uired, Disposed of	, or Beneficial	lv Owned	
1.Title of Security (Instr. 3)	2. Transaction E (Month/Day/Ye	ar) Execution any		3. Transactic Code (Instr. 8)	4. Securitie on(A) or Disp (Instr. 3, 4	es Acqueosed co and 5) (A) or	uired of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	•	
Common Stock	12/11/2012			Code V P	Amount 120,000	(D) A	Price \$ 1.2		D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Li Xinzhou - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
here and a second second second			10% Owner	Officer	Other			
Li Xinzhou PRES. NAQU AREA PIONEER PHARMA CO. LTD. NO. 1000, WANGQIAO ROAD, PUDONG AREA SHANGHAI, P.R. OF CHINA 201201		х			Pres.Naqu Area Pioneer Pharma			
Signatures								
/s/ Xinzhou (Paul) Li	01/03/2013							

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) As President and sole owner of Naqu Area Pioneer Pharma Co. Ltd., the parent company of Pioneer Pharma (Singapore) who owns 2,000,000 shares of NovaBay, Mr. Paul Li is the beneficial owner of such 2,000,000 NovaBay shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.